Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi

The life span of thalassemia major patients has been extended with early diagnosis and treatment modalities. This condition has resulted in an increase in osteoporosis-related problems. Even with optimal transfusions, the bone marrow of these patients remains hyperactive. For this reason, despite bl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Türkiye fiziksel tip ve rehabilitasyon dergisi 2012-06, Vol.58 (2), p.154
Hauptverfasser: Yigitoglu, Pembe Hare, Guzel, Rengin, Evran, Mehtap, Gurkan, Emel
Format: Artikel
Sprache:tur
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 154
container_title Türkiye fiziksel tip ve rehabilitasyon dergisi
container_volume 58
creator Yigitoglu, Pembe Hare
Guzel, Rengin
Evran, Mehtap
Gurkan, Emel
description The life span of thalassemia major patients has been extended with early diagnosis and treatment modalities. This condition has resulted in an increase in osteoporosis-related problems. Even with optimal transfusions, the bone marrow of these patients remains hyperactive. For this reason, despite blood transfusion, iron chelation, and sex hormone replacement therapy, generalized osteoporosis and osteopenia are still frequent in thalassemia patients. In thalassemia-induced osteoporosis, bone resorption increases. This condition makes biphosphonates, which are potent inhibitors of osteoclast function, the drug of choice. ln this article, two sisters with thalassemia major and secondary osteoporosis are discussed and the results of treatment with intermittent zoledronic acid (iv. 4 mg) for 6 years are presented. We also performed a review of the literature on the etiopathogenesis of thalasemia-induced osteoporosis and the treatment modalities. Key Words: Thalassemia, osteoporosis, zoledronic acid Talasemi major hastalarinda, erken tani ve uygulanan tedaviler ile yasam suresinin uzamasiyla birlikte, osteoporozla iliskili sorunlar belirgin sekilde artmistir. Bu hastalarda optimal transfuzyonlarla bile kemik iligi hiperaktif kalmaktadir. Bu nedenle transfuzyonlar, demir selasyonu ve seks hormonlariyla optimal tedaviye ragmen jeneralize osteoporoz ve osteopeni talasemide sik gorulmektedir. Talasemiye bagli osteoporozda kemik rezorbsiyonunun artmis olmasi osteoklast fonksiyonunun potent inhibitorleri olan bifosfonatlarin kullanimini gundeme getirmistir. Bu makalede talasemi major ve sekonder osteoporoz tanilariyla takip edilen iki kizkardes tartisilmakta ve 6 yil sure ile uygulanan 4 mg aralikli zoledronik asit tedavisinin sonuclari sunulmaktadir. Talasemide gelisen osteoporozun etyopatogenezi ve uygulanan tedavi yaklasimlari gozden gecirilmektedir. Anahtar Kelimeler: Talasemi, osteoporoz, zoledronik asit
doi_str_mv 10.4274/tftr.57704
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A352489929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A352489929</galeid><sourcerecordid>A352489929</sourcerecordid><originalsourceid>FETCH-LOGICAL-g709-d97a65999266d6458dad29916f3cd324fd2c5608ba9aafbd3e508bff0d4a6193</originalsourceid><addsrcrecordid>eNpNj81OQjEQhe9CExHd-ARdubvQ-0_ZEeJfQuJCXJuhncJIac1tCwkP6TNZoolkFjNzMuc7mSy7K_ioLrt6HHToR03X8foiGxQVL3NeVvVVdu39J-dN10z4IPt-98icZkdnUPXOkmQgSTGyLGzAgPe4I8jJqihRMecDui_XO09-ysLBMQkJ0GPSgmdgVZr3hIcTM2yQGQrYQ4g9jpcnXKL9Q47RKviP3jLwFNg2GgOWdjRltE3XZh2ZjzbuItufAaNla3dUmBpK6sns0NNNdqnBeLz968Ps7fFhOX_OF69PL_PZIl93XORKdNA2QoiybVVbNxMFqhSiaHUlVVXWWpWyaflkBQJAr1SFTVq05qqGthDVMBv9Utdg8IOsdqEHmUql96SzqCnps6op60kKORnuzwwbBBM23pkYyFl_fvgDAUKQqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yigitoglu, Pembe Hare ; Guzel, Rengin ; Evran, Mehtap ; Gurkan, Emel</creator><creatorcontrib>Yigitoglu, Pembe Hare ; Guzel, Rengin ; Evran, Mehtap ; Gurkan, Emel</creatorcontrib><description>The life span of thalassemia major patients has been extended with early diagnosis and treatment modalities. This condition has resulted in an increase in osteoporosis-related problems. Even with optimal transfusions, the bone marrow of these patients remains hyperactive. For this reason, despite blood transfusion, iron chelation, and sex hormone replacement therapy, generalized osteoporosis and osteopenia are still frequent in thalassemia patients. In thalassemia-induced osteoporosis, bone resorption increases. This condition makes biphosphonates, which are potent inhibitors of osteoclast function, the drug of choice. ln this article, two sisters with thalassemia major and secondary osteoporosis are discussed and the results of treatment with intermittent zoledronic acid (iv. 4 mg) for 6 years are presented. We also performed a review of the literature on the etiopathogenesis of thalasemia-induced osteoporosis and the treatment modalities. Key Words: Thalassemia, osteoporosis, zoledronic acid Talasemi major hastalarinda, erken tani ve uygulanan tedaviler ile yasam suresinin uzamasiyla birlikte, osteoporozla iliskili sorunlar belirgin sekilde artmistir. Bu hastalarda optimal transfuzyonlarla bile kemik iligi hiperaktif kalmaktadir. Bu nedenle transfuzyonlar, demir selasyonu ve seks hormonlariyla optimal tedaviye ragmen jeneralize osteoporoz ve osteopeni talasemide sik gorulmektedir. Talasemiye bagli osteoporozda kemik rezorbsiyonunun artmis olmasi osteoklast fonksiyonunun potent inhibitorleri olan bifosfonatlarin kullanimini gundeme getirmistir. Bu makalede talasemi major ve sekonder osteoporoz tanilariyla takip edilen iki kizkardes tartisilmakta ve 6 yil sure ile uygulanan 4 mg aralikli zoledronik asit tedavisinin sonuclari sunulmaktadir. Talasemide gelisen osteoporozun etyopatogenezi ve uygulanan tedavi yaklasimlari gozden gecirilmektedir. Anahtar Kelimeler: Talasemi, osteoporoz, zoledronik asit</description><identifier>ISSN: 1302-0234</identifier><identifier>DOI: 10.4274/tftr.57704</identifier><language>tur</language><publisher>Galenos Yayinevi Tic. Ltd</publisher><subject>Hormone therapy ; Osteoporosis ; Thalassemia</subject><ispartof>Türkiye fiziksel tip ve rehabilitasyon dergisi, 2012-06, Vol.58 (2), p.154</ispartof><rights>COPYRIGHT 2012 Galenos Yayinevi Tic. Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Yigitoglu, Pembe Hare</creatorcontrib><creatorcontrib>Guzel, Rengin</creatorcontrib><creatorcontrib>Evran, Mehtap</creatorcontrib><creatorcontrib>Gurkan, Emel</creatorcontrib><title>Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi</title><title>Türkiye fiziksel tip ve rehabilitasyon dergisi</title><description>The life span of thalassemia major patients has been extended with early diagnosis and treatment modalities. This condition has resulted in an increase in osteoporosis-related problems. Even with optimal transfusions, the bone marrow of these patients remains hyperactive. For this reason, despite blood transfusion, iron chelation, and sex hormone replacement therapy, generalized osteoporosis and osteopenia are still frequent in thalassemia patients. In thalassemia-induced osteoporosis, bone resorption increases. This condition makes biphosphonates, which are potent inhibitors of osteoclast function, the drug of choice. ln this article, two sisters with thalassemia major and secondary osteoporosis are discussed and the results of treatment with intermittent zoledronic acid (iv. 4 mg) for 6 years are presented. We also performed a review of the literature on the etiopathogenesis of thalasemia-induced osteoporosis and the treatment modalities. Key Words: Thalassemia, osteoporosis, zoledronic acid Talasemi major hastalarinda, erken tani ve uygulanan tedaviler ile yasam suresinin uzamasiyla birlikte, osteoporozla iliskili sorunlar belirgin sekilde artmistir. Bu hastalarda optimal transfuzyonlarla bile kemik iligi hiperaktif kalmaktadir. Bu nedenle transfuzyonlar, demir selasyonu ve seks hormonlariyla optimal tedaviye ragmen jeneralize osteoporoz ve osteopeni talasemide sik gorulmektedir. Talasemiye bagli osteoporozda kemik rezorbsiyonunun artmis olmasi osteoklast fonksiyonunun potent inhibitorleri olan bifosfonatlarin kullanimini gundeme getirmistir. Bu makalede talasemi major ve sekonder osteoporoz tanilariyla takip edilen iki kizkardes tartisilmakta ve 6 yil sure ile uygulanan 4 mg aralikli zoledronik asit tedavisinin sonuclari sunulmaktadir. Talasemide gelisen osteoporozun etyopatogenezi ve uygulanan tedavi yaklasimlari gozden gecirilmektedir. Anahtar Kelimeler: Talasemi, osteoporoz, zoledronik asit</description><subject>Hormone therapy</subject><subject>Osteoporosis</subject><subject>Thalassemia</subject><issn>1302-0234</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNpNj81OQjEQhe9CExHd-ARdubvQ-0_ZEeJfQuJCXJuhncJIac1tCwkP6TNZoolkFjNzMuc7mSy7K_ioLrt6HHToR03X8foiGxQVL3NeVvVVdu39J-dN10z4IPt-98icZkdnUPXOkmQgSTGyLGzAgPe4I8jJqihRMecDui_XO09-ysLBMQkJ0GPSgmdgVZr3hIcTM2yQGQrYQ4g9jpcnXKL9Q47RKviP3jLwFNg2GgOWdjRltE3XZh2ZjzbuItufAaNla3dUmBpK6sns0NNNdqnBeLz968Ps7fFhOX_OF69PL_PZIl93XORKdNA2QoiybVVbNxMFqhSiaHUlVVXWWpWyaflkBQJAr1SFTVq05qqGthDVMBv9Utdg8IOsdqEHmUql96SzqCnps6op60kKORnuzwwbBBM23pkYyFl_fvgDAUKQqQ</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Yigitoglu, Pembe Hare</creator><creator>Guzel, Rengin</creator><creator>Evran, Mehtap</creator><creator>Gurkan, Emel</creator><general>Galenos Yayinevi Tic. Ltd</general><scope/></search><sort><creationdate>20120601</creationdate><title>Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi</title><author>Yigitoglu, Pembe Hare ; Guzel, Rengin ; Evran, Mehtap ; Gurkan, Emel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g709-d97a65999266d6458dad29916f3cd324fd2c5608ba9aafbd3e508bff0d4a6193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>tur</language><creationdate>2012</creationdate><topic>Hormone therapy</topic><topic>Osteoporosis</topic><topic>Thalassemia</topic><toplevel>online_resources</toplevel><creatorcontrib>Yigitoglu, Pembe Hare</creatorcontrib><creatorcontrib>Guzel, Rengin</creatorcontrib><creatorcontrib>Evran, Mehtap</creatorcontrib><creatorcontrib>Gurkan, Emel</creatorcontrib><jtitle>Türkiye fiziksel tip ve rehabilitasyon dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yigitoglu, Pembe Hare</au><au>Guzel, Rengin</au><au>Evran, Mehtap</au><au>Gurkan, Emel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi</atitle><jtitle>Türkiye fiziksel tip ve rehabilitasyon dergisi</jtitle><date>2012-06-01</date><risdate>2012</risdate><volume>58</volume><issue>2</issue><spage>154</spage><pages>154-</pages><issn>1302-0234</issn><abstract>The life span of thalassemia major patients has been extended with early diagnosis and treatment modalities. This condition has resulted in an increase in osteoporosis-related problems. Even with optimal transfusions, the bone marrow of these patients remains hyperactive. For this reason, despite blood transfusion, iron chelation, and sex hormone replacement therapy, generalized osteoporosis and osteopenia are still frequent in thalassemia patients. In thalassemia-induced osteoporosis, bone resorption increases. This condition makes biphosphonates, which are potent inhibitors of osteoclast function, the drug of choice. ln this article, two sisters with thalassemia major and secondary osteoporosis are discussed and the results of treatment with intermittent zoledronic acid (iv. 4 mg) for 6 years are presented. We also performed a review of the literature on the etiopathogenesis of thalasemia-induced osteoporosis and the treatment modalities. Key Words: Thalassemia, osteoporosis, zoledronic acid Talasemi major hastalarinda, erken tani ve uygulanan tedaviler ile yasam suresinin uzamasiyla birlikte, osteoporozla iliskili sorunlar belirgin sekilde artmistir. Bu hastalarda optimal transfuzyonlarla bile kemik iligi hiperaktif kalmaktadir. Bu nedenle transfuzyonlar, demir selasyonu ve seks hormonlariyla optimal tedaviye ragmen jeneralize osteoporoz ve osteopeni talasemide sik gorulmektedir. Talasemiye bagli osteoporozda kemik rezorbsiyonunun artmis olmasi osteoklast fonksiyonunun potent inhibitorleri olan bifosfonatlarin kullanimini gundeme getirmistir. Bu makalede talasemi major ve sekonder osteoporoz tanilariyla takip edilen iki kizkardes tartisilmakta ve 6 yil sure ile uygulanan 4 mg aralikli zoledronik asit tedavisinin sonuclari sunulmaktadir. Talasemide gelisen osteoporozun etyopatogenezi ve uygulanan tedavi yaklasimlari gozden gecirilmektedir. Anahtar Kelimeler: Talasemi, osteoporoz, zoledronik asit</abstract><pub>Galenos Yayinevi Tic. Ltd</pub><doi>10.4274/tftr.57704</doi></addata></record>
fulltext fulltext
identifier ISSN: 1302-0234
ispartof Türkiye fiziksel tip ve rehabilitasyon dergisi, 2012-06, Vol.58 (2), p.154
issn 1302-0234
language tur
recordid cdi_gale_infotracacademiconefile_A352489929
source EZB-FREE-00999 freely available EZB journals
subjects Hormone therapy
Osteoporosis
Thalassemia
title Use of zoledronic acid in thalassemia-induced osteoporosis: two case reports and review of the literature/Talasemi osteoporozunda zoledronik asit kullanimi: iki olgu sunumu ve literaturun gozden gecirilmesi
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A59%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20zoledronic%20acid%20in%20thalassemia-induced%20osteoporosis:%20two%20case%20reports%20and%20review%20of%20the%20literature/Talasemi%20osteoporozunda%20zoledronik%20asit%20kullanimi:%20iki%20olgu%20sunumu%20ve%20literaturun%20gozden%20gecirilmesi&rft.jtitle=Tu%CC%88rkiye%20fiziksel%20tip%20ve%20rehabilitasyon%20dergisi&rft.au=Yigitoglu,%20Pembe%20Hare&rft.date=2012-06-01&rft.volume=58&rft.issue=2&rft.spage=154&rft.pages=154-&rft.issn=1302-0234&rft_id=info:doi/10.4274/tftr.57704&rft_dat=%3Cgale%3EA352489929%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A352489929&rfr_iscdi=true